



Used in Lieu of PTO/SB/08A/B
(Based on PTO 10-07 version)

Substitute for form 1449/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/715,229-Conf. #5733
		Filing Date	November 17, 2003
		First Named Inventor	Tariq M. RANA
		Art Unit	1635
		Examiner Name	K. Chong
Sheet	1	of	4
		Attorney Docket Number	UMY-041RCE

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.†	Document Number Number-Kind Code* (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1*	US-5,782,242	02-16-1999	Monia	
	A2*	US-6,358,932	03-19-2002	Monia	
	A3*	US-20020086356-A1	07-04-2002	Tuschi et al.	
	A4*	US-20030051263-A1	03-13-2003	Fire et al.	
	A5*	US-20030055020-A1	03-20-2003	Fire et al.	
	A6*	US-20030056235-A1	03-20-2003	Fire et al.	
	A7*	US-20030069195-A1	04-10-2003	Farrar et al.	
	A8*	US-20030108923-A1	06-12-2003	Tuschi et al.	
	A9*	US-20030144232	07-31-2003	Agami et al.	
	A10*	US-20030144239-A1	07-31-2003	Agami et al.	
	A11*	US-20030180756-A1	09-25-2003	Shi et al.	
	A12*	US-20030190635-A1	10-09-2003	McSwiggen	
	A13*	US-20040023390-A1	02-05-2004	Davidson et al.	
	A14*	US-20040203145-A1	10-14-2004	Zamore et al.	
	A15*	US-20040214198-A1	10-28-2004	Rana	
	A16*	US-20040219671-A1	11-04-2004	McSwiggen et al.	
	A17*	US-20040229266-A1	11-18-2004	Tuschi et al.	
	A18*	US-20040241854-A1	12-02-2004	Davidson et al.	
	A19*	US-20040259247-A1	12-23-2004	Tuschi et al.	
	A20*	US-20040259248-A1	12-23-2004	Tuschi et al.	
	A21*	US-20050026278-A1	02-03-2005	Tuschi et al.	
	A22*	US-20050037988-A1	02-17-2005	Zamore et al.	
	A23*	US-20050042646-A1	02-24-2005	Davidson et al.	
	A24*	US-20050096284-A1	05-05-2005	McSwiggen	
	A25*	US-20050106731-A1	05-19-2005	Davidson et al.	
	A26*	US-20050130184-A1	06-16-2005	Xu et al.	
	A27*	US-20050130919-A1	06-16-2005	Xu et al.	
	A28*	US-20050137155-A1	06-23-2005	McSwiggen et al.	
	A29*	US-20050181382-A1	08-18-2005	Zamore et al.	
	A30*	US-20050186586-A1	08-25-2005	Zamore et al.	
	A31*	US-20050191638	09-01-2005	McSwiggen	
	A32*	US-20050234006-A1	10-20-2005	Tuschi et al.	
	A33*	US-20050234007-A1	10-20-2005	Tuschi et al.	
	A34*	US-20050255086-A1	11-17-2005	Davidson et al.	
	A35*	US-20050277133-A1	12-15-2005	McSwiggen	
	A36*	US-20060009402-A1	01-12-2006	Zamore et al.	
	A37*	US-20060009408-A1	01-12-2006	Davidson et al.	
	A38*	US-20060270623-A1	11-30-2006	McSwiggen	
	A39*	US-20070003960-A1	01-04-2007	Tuschi et al.	
	A40*	US-20070003962-A1	01-04-2007	Tuschi et al.	
	A41*	US-20070003963-A1	01-04-2007	Tuschi et al.	
	A42*	US-7,241,618-A1	07-10-2007	Agami et al.	

Examiner Signature	Date Considered
--------------------	-----------------

Substitute for form 1449/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/715,229-Conf. #5733
		Filing Date	November 17, 2003
		First Named Inventor	Tariq M. RANA
		Art Unit	1635
		Examiner Name	K. Chong
Sheet	2	of	4
		Attorney Docket Number	UMY-041RCE

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	†
		Country Code ² -Number ³ -Kind Code ⁴ (if known)				
	B1	WO-94/19493-A1	09-01-1994	The General Hospital Corp. et al.		
	B2	WO-98/48009-A2	10-29-1998	University of Florida		
	B3	WO-01/75164-A2	10-11-2001	Whitehead Institute for Biomedical Research et al		
	B4	WO-03/006477-A1	01-23-2003	University of Massachusetts		
	B5	WO-03/056012-A1	07-10-2003	Cancer Research Technology, Ltd.		
	B6	WO-03/070895-A2	08-28-2003	Ribozyme Pharmaceuticals, Inc.		
	B7	WO-03/080807-A2	10-02-2003	President and Fellows of Harvard College		
	B8	WO-04/013280-A2	02-12-2004	University of Iowa Research Foundation		
	B9	WO-2004/013310-A2	02-12-2004	Intradigm Corporation		
	B10	WO-2004/014933-A1	02-19-2004	University of Massachusetts		
	B11	WO-04/042027-A2	05-21-2004	University of Massachusetts		
	B12	WO-04/046324-A2	06-03-2004	University of Massachusetts		
	B13	WO-04/058940-A2	07-15-2004	University of Iowa Research Foundation		
	B14	WO-04/001335-A2	12-31-2003	Honeywell International Inc.		
	B15	WO-05/001043-A2	01-06-2005	University of Massachusetts		
	B16	WO-05/003350-A2	01-13-2005	Sirna Therapeutics, Inc.		
	B17	WO-05/007875-A2	01-27-2005	University of Massachusetts		
	B18	WO-05/007877-A2	01-27-2005	University of Massachusetts		
	B19	WO-05/019453-A2	03-03-2005	Sirna Therapeutics, Inc.		
	B20	WO-05/023991-A2	03-17-2005	The General Hospital Corp.		
	B21	WO-05/027980-A1	03-31-2005	University of Massachusetts		
	B22	WO-05/045034-A2	05-19-2005	Sirna Therapeutics, Inc.		

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ CITE NO.: Those application(s) which are marked with an single asterisk () next to the Cite No. are not supplied (under 37 CFR 1.589(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the FRW. ² Applicant's unique citation designation number (optional). ³ See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.18 if possible. ⁷ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published				T*
	C1	Abdelgany, Amr et al., "Allele-specific silencing of a pathogenic mutant acetylcholine receptor subunit by RNA interference," <i>Human Molecular Genetics</i> , Vol. 12(20):2637-2644 (2003)				
	C2	Amarguicui, Mohammed et al., "Tolerance for mutations and chemical modifications in a siRNA," <i>Nucleic Acids Research</i> , Vol. 31(2):589-595 (2003)				
	C3	Behndig, Anders et al., "In Vitro Photochemical Cataract in Mice Lacking Copper-Zinc				
Examiner Signature				Date Considered		

Substitute for form 1449/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/715,229-Conf. #5733
				Filing Date	November 17, 2003
				First Named Inventor	Tariq M. RANA
				Art Unit	1635
				Examiner Name	K. Chong
Sheet	3	of	4	Attorney Docket Number	UMY-041RCE

		Superoxide Dismutase," <i>Free Radical Biology & Medicine</i> , Vol. 31(6):738-744 (2001)	
C4	Boutia, Alexandra et al., "Short 5'-phosphorylated double-stranded RNAs induce RNA interference in <i>Drosophila</i> ," <i>Current Biology</i> , Vol. 11:1776-1780 (2001)		
C5	Brummelkamp, Thijn R. et al., "A System for Stable Expression of Short Interfering RNAs in Mammalian Cells," retrieved online at: Scienceexpress.www.scienceexpress.org/21March2002/page1/10.1126/Science.1068999		
C6	Brummelkamp, Thijn R. et al., "Stable suppression of tumorigenicity by virus-mediated RNA interference," <i>Cancer Cell</i> , Vol. 2:243-247 (2002)		
C7	Caplen, Natasha J. et al., "Rescue of polyglutamine-mediated cytotoxicity by double-stranded RNA-mediated RNA interference," <i>Human Molecular Genetics</i> , Vol. 11(2):175-184 (2002)		
C8	Cleveland, Don W. et al., "From Charcot to Lou Gehrig: Deciphering Selective Motor Neuron Death in ALS," <i>Nature Reviews Neuroscience</i> , Vol. 2:806-819 (2001)		
C9	Devroe, Eric et al., "Retrovirus-delivered siRNA," <i>BMC Biotechnology</i> , Vol. 2(15):1-5 (2002)		
C10	Ding, Hongliu et al., "Selective silencing by RNAi of a dominant allele that causes amyotrophic lateral sclerosis," <i>Aging Cell</i> , Vol. 2:209-217 (2003)		
C11	Flood, Dorothy G. et al., "Hindlimb Motor Neurons Require Cu/Zn Superoxide Dismutase for Maintenance of Neuromuscular Junctions," <i>American Journal of Pathology</i> , Vol. 155(2):663-672 (1999)		
C12	Fluiter, Kees et al., "Tumor Genotype-specific Growth Inhibition <i>In Vivo</i> by Antisense Oligonucleotides against a Polymorphic Site of the Large Subunit of Human RNA Polymerase II," <i>Cancer Research</i> , Vol. 62:2024-2028 (2002)		
C13	Hammond, Scott M. et al., "An RNA-directed nuclease mediates post-transcriptional gene silencing in <i>Drosophila</i> cells," <i>Nature</i> , Vol. 404:293-296 (2000)		
C14	Harper, Scott Q. et al., "RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model," <i>PNAS</i> , Vol. 102(16):5820-5825 (2005)		
C15	Kawase, Makoto et al., "Exacerbation of Delayed Cell Injury After Transient Global Ischemia in Mutant Mice With CuZn Superoxide Dismutase Deficiency," <i>Stroke</i> , Vol. 30:1962-1968 (1999)		
C16	Klug, N. et al., "A selective antisense oligonucleotide against the G93A mutant of the CuZn-SOD1 mRNA, applied to the mouse brain," <i>European Journal of Physiology</i> , Vol. 441(Suppl. 6):R205, No. P20-7 (2001)		
C17	Kondo, Takeo et al., "Reduction of CuZn-Superoxide Dismutase Activity Exacerbates Neuronal Cell Injury and Edema Formation after Transient focal Cerebral Ischemia," <i>The Journal of Neuroscience</i> , Vol. 17(11):4180-4189 (1997)		
C18	Kunst, Catherine B. et al., "Mutations in <i>SOD1</i> associated with amyotrophic lateral sclerosis cause novel protein interactions," <i>Nature Genetics</i> , Vol. 15:91-94 (1997)		
C19	Lipardi, Concetta et al., "RNAi as Random Degradable PCR: siRNA Primers Convert mRNA into dsRNAs that Are Degraded to Generate New siRNAs," <i>Cell</i> , Vol. 107:297-307 (2001)		
C20	Luyten, Ingrid et al., "Hybridization properties of base-modified oligonucleotides within the double and triple helix motif," <i>Eur. J. Med. Chem.</i> , Vol. 33:515-576 (1998)		
C21	Matz, Paul G. et al., "Cell Death After Exposure to Subarachnoid Hemolysate Correlates Inversely With Expression of CuZn-Superoxide Dismutase," <i>Stroke</i> , Vol. 31:2450-2459 (2000)		
C22	Matzuk, Martin M. et al., "Ovarian Function in Superoxide Dismutase 1 and 2 Knockout Mice," <i>Endocrinology</i> , Vol. 139(9):4008-4011 (1998)		
C23	Maxwell, Michele M. et al., "RNA interference-mediated silencing of mutant superoxide dismutase rescues cyclosporin A-induced death in cultured neuroblastoma cells," <i>PNAS</i> , Vol. 101(9):3178-3183 (2004)		
C24	McManus, Michael T. et al., "Gene silencing using micro-RNA designed hairpins," <i>RNA</i> , Vol. 8:842-850 (2002)		
C25	Miller, Victor M. et al., "Allele-specific silencing of dominant disease genes," <i>PNAS</i> , Vol.		
Examiner Signature		Date Considered	



Used in Lieu of PTO/SB/08/A
(Based on PTO 10-07 version)

Substitute for form 1446/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/715,229-Conf. #5733
		Filing Date	November 17, 2003
		First Named Inventor	Tariq M. RANA
		Art Unit	1635
		Examiner Name	K. Chong
Sheet	4	of	4
		Attorney Docket Number	UMY-041RCE

		100(12):7195-7200 (2003)	
C26	Miller, V.M. et al., "Targeting Alzheimer's disease genes with RNA interference: an efficient strategy for silencing mutant alleles," <i>Nucleic Acids Research</i> , Vol. 32(2):661-668 (2004)		
C27	Miyagishi, Makoto et al., "U6 promoter-driven siRNAs with four uridine 3' overhangs efficiently suppress targeted gene expression in mammalian cells," <i>Nature Biotechnology</i> , Vol. 19:497-500 (2002)		
C28	Moss, Eric G., "Silencing unhealthy alleles naturally," <i>Trends in Biotechnology</i> , Vol. 21(5):185-187 (2003)		
C29	Paddison, Patrick J. et al., "Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells," <i>Genes & Development</i> , Vol. 16:948-958 (2002)		
C30	Paul, Cynthia P. et al., "Effective expression of small interfering RNA in human cells," <i>Nature Biotechnology</i> , Vol. 20:505-508 (2002)		
C31	Ralph, G. Scott et al., "Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model," <i>Nature Medicine</i> , Vol. 11(4):429-433 (2005)		
C32	Raoul, et al., "Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS," <i>Nature Medicine</i> , Vol. 11(4):423-428 (2005)		
C33	Rival, Thomas et al., "Decreasing Glutamate Buffering Capacity Triggers Oxidative Stress and Neurofil Degeneration in the <i>Drosophila</i> Brain," <i>Current Biology</i> , Vol. 14:599-605 (2004)		
C34	Schwarz, Dianne S. et al., "Evidence that siRNAs Function as Guides, Not Primers, in the <i>Drosophila</i> and Human RNAi Pathways," <i>Molecular Cell</i> , Vol. 10:537-548 (2002)		
C35	Shefner, J.M. et al., "Mice lacking cytosolic copper/zinc superoxide dismutase display a distinctive motor axonopathy," <i>Neurology</i> , Vol. 53:1239-1246 (1999)		
C36	Siddique, Teepu et al., "Molecular genetic basis of familial ALS," <i>Neurology</i> , Vol. 47(Suppl. 2):S27-S35 (1996)		
C37	Sui, Guangchao et al., "A DNA vector-based RNAi technology to suppress gene expression in mammalian cells," <i>PNAS</i> , Vol. 99(8):5515-5520 (2002)		
C38	Veldink, Jan H. et al., "The future of motor neuron disease, The challenge is in the genes," <i>J. Neurol.</i> , Vol. 251:491-500 (2004)		
C39	Victor, Martin et al., "HAT activity is essential for CBP-1-dependent transcription and differentiation in <i>Caenorhabditis elegans</i> ," <i>EMBO Reports</i> , Vol. 3(1):50-55 (2002)		
C40	Xia, Xu Gang et al., "An enhanced U6 promoter for synthesis of short hairpin RNA," <i>Nucleic Acids Research</i> , Vol. 31(17):1-5 (2003)		
C41	Xia, Xu Gang et al., "An RNAi strategy for treatment of amyotrophic lateral sclerosis caused by mutant Cu,Zn superoxide dismutase," <i>Journal of Neurochemistry</i> , Vol. 92:362-367 (2005)		
C42	Xia, Haibin et al., "siRNA-mediated gene silencing in vitro and in vivo," <i>Nature Biotechnology</i> , Vol. 20:1006-1010 (2002)		
C43	Xie, Xiongcong et al., "Effects of RNA Interference-mediated Silencing of γ -Secretase Complex Components on Cell Sensitivity to Caspase-3 Activation," <i>The Journal of Biological Chemistry</i> , Vol. 279(33):34130-34137 (2004)		
C44	Xie, Jun et al., "RNAi knockdown of Par-4 inhibits neurosynaptic degeneration in ALS-linked mice," <i>Journal of Neurochemistry</i> , Vol. 92:59-71 (2005)		
C45	Yu, Jenn-Yah et al., "RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells," <i>PNAS</i> , Vol. 99(9):6047-6052 (2002)		
C46	Zamore, Phillip D. et al., "RNAi: Double-Stranded RNA Directs the ATP-Dependent Cleavage of mRNA at 21 to 23 Nucleotide Intervals," <i>Cell</i> , Vol. 101:25-33 (2000)		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered
--------------------	-----------------